Personalis at Advances in Immuno-Oncology Congress, London: MAY 24-25, 2018


Erin Newburn, MS, PhD
Associate Director, Field Applications Scientist
Personalis, Inc.

Developing comprehensive tumor immunogenomics profiles with high-content assays and analytics  

Identifying more robust predictors of patient response to cancer immunotherapy may depend on finding the right combination of biomarkers—but few platforms support multi-dimensional biomarker analysis. This talk will feature Personalis ACE ImmunoID™, a combined whole exome and transcriptome platform, with analytics that elucidate neoantigens, tumor escape, and the tumor microenvironment. We will also discuss how our platform can be used to overcome the challenges of gaining high quality data from degraded samples, decreases the risk of missed variants, and will feature a case study demonstrating the ability of this platform to uncover tumor escape mechanisms.